

# Pathophysiology of Graft-Versus-Host Disease

Seminars in Hematology

43, 3-10

DOI: [10.1053/j.seminhematol.2005.09.001](https://doi.org/10.1053/j.seminhematol.2005.09.001)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immunopathology of Organ Transplantation. , 0, , 1-24.		0
2	Update on ocular graft versus host disease. <i>Current Opinion in Ophthalmology</i> , 2006, 17, 344-348.	1.3	84
3	Continuous infusion of coagulation factors: current opinion. <i>Current Opinion in Hematology</i> , 2006, 13, 308-315.	1.2	33
4	Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol. <i>Haemophilia</i> , 2006, 12, 663-667.	1.0	28
5	A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy. <i>Leukemia</i> , 2006, 20, 1557-1565.	3.3	52
6	Alloreaction increases or restores CD40, CD54, and/or HLA molecule expression in acute myelogenous leukemia blasts, through secretion of inflammatory cytokines: dominant role for TNF $\alpha$ , in concert with IFN $\gamma$ . <i>Leukemia</i> , 2006, 20, 1992-2001.	3.3	9
7	Sex-Dependent Attenuation of Plaque Growth After Treatment With Bone Marrow Mononuclear Cells. <i>Circulation Research</i> , 2007, 101, 1319-1327.	2.0	45
8	Treatment Options in Steroid-Refractory Acute Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1436-1444.	0.9	24
9	Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2007, 109, 5511-5519.	0.6	157
10	Hyperglycemia During the Neutropenic Period Is Associated With a Poor Outcome in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2007, 84, 814-820.	0.5	82
11	Human thymus regeneration and T cell reconstitution. <i>Seminars in Immunology</i> , 2007, 19, 280-288.	2.7	31
12	New Directions in the Genomics of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 127-144.	2.0	40
13	Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 369-370.	2.0	0
14	The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 521-529.	2.0	13
15	Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant Using the Fludarabine and Low-Dose Total-Body Irradiation 200-cGy. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 790-805.	2.0	10
16	Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 942-947.	2.0	21
17	A Novel Role for the Semaphorin Sema4D in the Induction of Allo-responses. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1294.e1-1294.e11.	2.0	16
18	Preoperative intravenous iron administration corrects anemia and reduces transfusion requirement in women undergoing abdominal hysterectomy. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2007, 9, 114-119.	0.2	29

#	ARTICLE	IF	CITATIONS
20	Dendritic cells and acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 1696-1701.	0.6	7
21	Immune Thrombocytopenic Purpura. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 743-759.	0.9	64
22	Pathophysiology of acute graft-versus-host disease: recent advances. <i>Translational Research</i> , 2007, 150, 197-214.	2.2	110
23	Novel strategies for the treatment and diagnosis of graft-versus-host-disease. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 91-97.	0.7	36
24	Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 4568.	3.0	10
25	Graft-Versus-Host Disease: A Surge of Developments. <i>PLoS Medicine</i> , 2007, 4, e198.	3.9	22
26	From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. <i>Journal of Cellular Physiology</i> , 2007, 211, 27-35.	2.0	578
27	Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 1001-1002.	1.3	22
28	A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. <i>Haemophilia</i> , 2007, 13, 256-263.	1.0	73
29	International workshop on immune tolerance induction: consensus recommendations. <i>Haemophilia</i> , 2007, 13, 1-22.	1.0	228
30	Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells. <i>Haemophilia</i> , 2007, 13, 61-64.	1.0	30
31	Chemical treatment of anti-CD results in improved efficacy for the inhibition of Fc $\gamma$ 3 receptor-mediated phagocytosis. <i>Transfusion</i> , 2007, 47, 2250-2259.	0.8	5
32	Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 143-150.	1.9	41
33	Mucosal graft-versus-host disease. <i>Oral Diseases</i> , 2007, 13, 519-529.	1.5	17
34	Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease. <i>Experimental Hematology</i> , 2007, 35, 274-286.	0.2	23
35	Comparative analysis of naïve and memory CD4+ and CD8+ T-cell subsets in bone marrow and G-CSF-mobilized peripheral blood stem cell allografts: impact of donor characteristics. <i>Experimental Hematology</i> , 2007, 35, 861-871.	0.2	16
36	Intravenous iron as a transfusion alternative. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2007, 9, 13-18.	0.2	1
37	Elevated serum cytokine levels are associated with human herpesvirus 6 reactivation in hematopoietic stem cell transplantation recipients. <i>Journal of Infection</i> , 2008, 57, 241-248.	1.7	38

#	ARTICLE	IF	CITATIONS
38	The immunopathology of thymic GVHD. <i>Seminars in Immunopathology</i> , 2008, 30, 439-456.	2.8	73
39	Oral graft-versus-host disease. <i>Oral Diseases</i> , 2008, 14, 396-412.	1.5	105
40	Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. <i>Bone Marrow Transplantation</i> , 2008, 41, 571-577.	1.3	31
41	Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model. <i>Gene Therapy</i> , 2008, 15, 171-182.	2.3	79
42	Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. <i>Vox Sanguinis</i> , 2008, 94, 172-183.	0.7	102
43	Understanding and harnessing the graft-versus-leukaemia effect. <i>British Journal of Haematology</i> , 2008, 142, 877-888.	1.2	78
44	Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. <i>Haemophilia</i> , 2008, 14, 138-146.	1.0	59
45	Management of surgery-associated bleeding in cancer patients. <i>Current Anaesthesia and Critical Care</i> , 2008, 19, 59-69.	0.3	2
46	Differential susceptibility of C57BL/6NCr and B6.Cg-Ptprca mice to commensal bacteria after whole body irradiation in translational bone marrow transplant studies. <i>Journal of Translational Medicine</i> , 2008, 6, 10.	1.8	20
47	The thymus in GVHD pathophysiology. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 119-128.	0.7	29
48	Study design and endpoints in graft-versus-host disease. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 357-372.	0.7	23
49	Imaging of Complications of Hematopoietic Stem Cell Transplantation. <i>Radiologic Clinics of North America</i> , 2008, 46, 397-417.	0.9	15
50	New treatment options for immune-mediated hematological disorders. <i>European Journal of Internal Medicine</i> , 2008, 19, 579-586.	1.0	4
51	Alemtuzumab for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 10-15.	2.0	72
52	Umbilical Cord Blood Transplantation after Reduced-Intensity Conditioning for Elderly Patients with Hematologic Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 583-590.	2.0	84
53	Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Postallogeneic Transplant Correlate with Graft-versus-Host Disease Severity and Overall Survival in Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 759-765.	2.0	36
54	Oral Graft-Versus-Host Disease. <i>Dental Clinics of North America</i> , 2008, 52, 79-109.	0.8	121
55	Impact of corticosteroid-related symptoms in patients with immune thrombocytopenic purpura: Results of a survey of 985 patients. <i>Clinical Therapeutics</i> , 2008, 30, 1540-1552.	1.1	22

#	ARTICLE	IF	CITATIONS
56	Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Cytokine and Growth Factor Reviews</i> , 2008, 19, 53-63.	3.2	30
57	Role of dendritic cells and chemokines in acute graft-versus-host disease. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 2065.	3.0	4
58	Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation. <i>The Cochrane Library</i> , 2008, , CD004885.	1.5	13
59	Immune tolerance induction for the eradication of inhibitors in patients with hemophilia A. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1885-1896.	1.4	4
60	Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 1611-1618.	0.8	187
61	Predominant donor CD103+CD8+ T cell infiltration into the gut epithelium during acute GvHD: a role of gut lymph nodes. <i>International Immunology</i> , 2008, 20, 385-394.	1.8	44
62	Association of Serum Interleukin-7 Levels With the Development of Acute Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2008, 26, 5735-5741.	0.8	88
63	In vivo "activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. <i>Blood</i> , 2008, 112, 2129-2138.	0.6	122
64	Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. <i>Blood</i> , 2008, 111, 1366-1377.	0.6	250
65	Organ-derived dendritic cells have differential effects on alloreactive T cells. <i>Blood</i> , 2008, 111, 2929-2940.	0.6	28
66	CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. <i>Blood</i> , 2008, 111, 4403-4412.	0.6	69
67	Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. <i>Blood</i> , 2008, 112, 1522-1529.	0.6	31
68	Biological Advances in Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2008, 85, 303-308.	0.5	25
69	Selective Effects of Cyclosporine A on Th2-Skewed Dendritic Cells Matured With Viral-Like Stimulus By Means of Toll-Like Receptors. <i>Transplantation</i> , 2008, 86, 880-884.	0.5	7
70	Tumor immunology and immunotherapy. , 2008, , 1181-1195.		0
71	Atherosclerosis as a disease of failed endogenous repair. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 3621.	3.0	33
72	Pathobiology of graft-versus-host disease. , 0, , 313-330.		0
73	Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, S4-S10.	0.5	11

#	ARTICLE	IF	CITATIONS
74	Emerging drugs for acute graft-versus-host disease. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 219-232.	1.0	5
75	Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand. <i>Journal of Immunology</i> , 2009, 183, 696-705.	0.4	28
76	The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD. <i>Cell Cycle</i> , 2009, 8, 1794-1802.	1.3	30
77	Essential biology of stem cell transplantation. , 2009, , 9-21.		3
78	Cryptococcosis in Solidâ€œOrgan, Hematopoietic Stem Cell, and Tissue Transplant Recipients: Evidenceâ€œBased Evolving Trends. <i>Clinical Infectious Diseases</i> , 2009, 48, 1566-1576.	2.9	100
79	Transfusion-Associated Graft-Versus-Host Disease. <i>Transfusion Medicine Reviews</i> , 2009, 23, 62-71.	0.9	106
80	A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. <i>Clinical Therapeutics</i> , 2009, 31, 679-691.	1.1	37
81	Upregulation of plasma CCL8 in mouse model of graft-vs-host disease. <i>Experimental Hematology</i> , 2009, 37, 525-531.	0.2	13
83	Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 484-498.	3.3	19
84	Oral carcinoma after hematopoietic stem cell transplantation â€œ a new classification based on a literature review over 30 years. <i>Head &amp; Neck Oncology</i> , 2009, 1, 29.	2.3	48
85	Patientsâ€™, physiciansâ€™, and pharmacistsâ€™ preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study. <i>Haemophilia</i> , 2009, 15, 473-486.	1.0	27
86	Improved quality of life for romiplostimâ€œtreated patients with chronic immune thrombocytopenic purpura: results from two randomized, placeboâ€œcontrolled trials. <i>British Journal of Haematology</i> , 2009, 144, 409-415.	1.2	150
87	The allogeneic graftâ€œversusâ€œcancer effect. <i>British Journal of Haematology</i> , 2009, 147, 614-633.	1.2	132
88	Reduction of disulfide bonds within antiâ€œD results in enhanced FcÎ³ receptor blockade. <i>Transfusion</i> , 2009, 49, 928-936.	0.8	2
89	Investigation of whether the acute hemolysis associated with Rh<sub>o</sub>(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model. <i>Transfusion</i> , 2009, 49, 1050-1058.	0.8	13
90	Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1824-1831.	1.9	46
91	Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects. <i>Cancer Treatment Reviews</i> , 2009, 35, 653-661.	3.4	28
92	GVHD: A Continuing Barrier to the Safety of Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 162-168.	2.0	26

#	ARTICLE	IF	CITATIONS
93	Rabbit Anti T-Lymphocyte Globulin Induces Apoptosis in Peripheral Blood Mononuclear Cell Compartments and Leukemia Cells, While Hematopoietic Stem Cells Are Apoptosis Resistant. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 173-182.	2.0	48
94	Recombinant Human Granulocyte Colony-Stimulating Factor Significantly Decreases the Expression of CXCR3 and CCR6 on T Cells and Preferentially Induces T helper Cells to a T helper 17 Phenotype in Peripheral Blood Harvests. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 835-843.	2.0	21
95	Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1331-1336.	2.0	13
96	Advances in hematologic stem cell transplant: An update for oral health care providers. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2009, 107, 301-312.	1.6	52
97	Pathology of graft-versus-host disease in the gastrointestinal tract. <i>Human Pathology</i> , 2009, 40, 909-917.	1.1	229
98	Romiplostim. <i>Drugs</i> , 2009, 69, 307-317.	4.9	20
99	Mouse models of graft-versus-host disease. <i>Stembook</i> , 2009, , .	0.3	15
100	An update on iron physiology. <i>World Journal of Gastroenterology</i> , 2009, 15, 4617.	1.4	277
101	Anatomic Pathology. , 2008, , 154-154.		0
102	Optimising immune tolerance induction strategies in the management of haemophilia patients with inhibitors: a cost-minimisation analysis. <i>Current Medical Research and Opinion</i> , 2009, 25, 239-250.	0.9	8
104	Therapeutic Approaches to Secondary Immune Thrombocytopenic Purpura. <i>Seminars in Hematology</i> , 2009, 46, S44-S58.	1.8	16
105	Graft-versus-host disease. <i>Lancet, The</i> , 2009, 373, 1550-1561.	6.3	2,093
106	Interleukin-17-Producing T-Helper Cells as New Potential Player Mediating Graft-Versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2009, 88, 1261-1272.	0.5	108
107	A biomarker panel for acute graft-versus-host disease. <i>Blood</i> , 2009, 113, 273-278.	0.6	348
108	Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 113, 6477-6484.	0.6	149
109	Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. <i>Blood</i> , 2009, 114, 3693-3706.	0.6	28
110	Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. <i>Blood</i> , 2009, 114, 891-900.	0.6	257
111	Acute graft-versus-host disease: from the bench to the bedside. <i>Blood</i> , 2009, 114, 4327-4336.	0.6	257

#	ARTICLE	IF	CITATIONS
112	Current insights into ocular graft-versus-host disease. <i>Current Opinion in Ophthalmology</i> , 2010, 21, 485-494.	1.3	68
113	Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. <i>Blood</i> , 2010, 115, 2319-2328.	0.6	48
114	Mild haemophilia: a disease with many faces and many unexpected pitfalls. <i>Haemophilia</i> , 2010, 16, 100-106.	1.0	45
115	Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. <i>Bone Marrow Transplantation</i> , 2010, 45, 385-391.	1.3	53
116	Absence of IL-23p19 in donor allogeneic cells reduces mortality from acute GVHD. <i>Bone Marrow Transplantation</i> , 2010, 45, 712-722.	1.3	20
117	Many faces of graft-versus-host disease. <i>Australasian Journal of Dermatology</i> , 2010, 51, 1-10.	0.4	46
118	STAT3 Signaling in CD4+ T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model. <i>Journal of Immunology</i> , 2010, 184, 764-774.	0.4	84
119	Effects of Bisphosphonate Administration on the Bone Mass in Immune Thrombocytopenic Purpura Patients Under Treatment With Steroids. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 622-627.	0.7	8
120	Expansion and Activation Kinetics of Immune Cells during Early Phase of GVHD in Mouse Model Based on Chemotherapy Conditioning. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-13.	3.3	16
121	The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2010, 51, 376-389.	0.6	34
122	Suicide gene therapy for graft-versus-host disease. <i>Immunotherapy</i> , 2010, 2, 521-537.	1.0	5
123	A Crucial Role for Host APCs in the Induction of Donor CD4+CD25+ Regulatory T Cell-Mediated Suppression of Experimental Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2010, 185, 3866-3872.	0.4	47
124	Pathogenesis and Management of Graft-versus-Host Disease. <i>Immunology and Allergy Clinics of North America</i> , 2010, 30, 75-101.	0.7	165
125	Effects of nilotinib on regulatory T cells: the dose matters. <i>Molecular Cancer</i> , 2010, 9, 22.	7.9	25
126	The role of HLA in umbilical cord blood transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 179-187.	0.7	18
127	Immune Reconstitution: How It Should Work, What's Broken, and Why It Matters. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S133-S137.	2.0	27
128	Glucocorticoid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1504-1518.	2.0	63
129	Identification of Stem Cell Transcriptional Programs Normally Expressed in Embryonic and Neural Stem Cells in Alloreactive CD8+ T Cells Mediating Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 751-771.	2.0	19



#	ARTICLE	IF	CITATIONS
130	The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 739-750.	2.0	7
131	Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1728-1737.	2.0	25
132	Sarcoidosis-associated MHC Ags and the development of cutaneous and nodal granulomas following allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2011, 46, 1032-1034.	1.3	5
133	Disorders of iron metabolism. Part II: iron deficiency and iron overload. <i>Journal of Clinical Pathology</i> , 2011, 64, 287-296.	1.0	229
134	Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without Abrogating the Graft-versus-Leukemia Effect in Murine Models. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1154-1168.	2.0	46
135	Pathophysiology, prevention, and treatment of acute graft-versus-host disease. <i>Transplant Research and Risk Management</i> , 0, , 31.	0.7	0
136	Management of the Medically Compromised Patient: Hematologic Disorders, Cancer, Hepatitis, and AIDS. , 2011, , 487-509.		1
137	Ceacam1 Separates Graft-versus-Host-Disease from Graft-versus-Tumor Activity after Experimental Allogeneic Bone Marrow Transplantation. <i>PLoS ONE</i> , 2011, 6, e21611.	1.1	3
138	The Involvement of Epithelial Fas in a Human Model of Graft Versus Host Disease. <i>Transplantation</i> , 2011, 91, 946-951.	0.5	11
139	Human peripheral blood CD4 T cell-engrafted non-obese diabetic- <i>scid</i> IL2r <sup>3</sup> -null H2-Ab1 tm1GruTg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , 2011, 166, 269-280.	1.1	88
140	Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). <i>Haemophilia</i> , 2011, 17, 407-411.	1.0	26
141	The role of regulatory T cells during the attenuation of graft-versus-leukemia activity following donor leukocyte infusion in mice. <i>Leukemia Research</i> , 2011, 35, 1549-1556.	0.4	6
142	Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract. <i>Experimental Hematology</i> , 2011, 39, 238-249.e1.	0.2	30
143	Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells. <i>Experimental Hematology</i> , 2011, 39, 710-720.	0.2	11
144	Early expression of plasma CCL8 closely correlates with survival rate of acute graft-vs.-host disease in mice. <i>Experimental Hematology</i> , 2011, 39, 1101-1112.	0.2	19
145	Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. <i>Clinical Oral Investigations</i> , 2011, 15, 127-139.	1.4	65
146	Control of mouse graft-versus-host disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference. <i>Immunology Letters</i> , 2011, 136, 194-202.	1.1	6
147	Advances in medical decision support systems for diagnosis of acute graft-versus-host disease: molecular and computational intelligence joint approaches. <i>Frontiers in Biology</i> , 2011, 6, 263.	0.7	7

#	ARTICLE	IF	CITATIONS
148	Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. American Journal of Hematology, 2011, 86, 278-291.	2.0	21
149	Immunomodulatory Effects of Intravenous Immunoglobulins (IVIGs) in HIV-1 Disease: A Systematic Review. International Reviews of Immunology, 2011, 30, 44-66.	1.5	7
150	Instability of Foxp3 Expression Limits the Ability of Induced Regulatory T Cells to Mitigate Graft versus Host Disease. Clinical Cancer Research, 2011, 17, 3969-3983.	3.2	81
151	Relationship between TNFA, TNFB and TNFR1 gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in a Chinese population. Bone Marrow Transplantation, 2011, 46, 400-407.	1.3	17
152	GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome. Bone Marrow Transplantation, 2011, 46, 668-675.	1.3	22
153	Loss of B7-H1 Expression by Recipient Parenchymal Cells Leads to Expansion of Infiltrating Donor CD8+ T Cells and Persistence of Graft-Versus-Host Disease. Journal of Immunology, 2012, 188, 724-734.	0.4	30
154	New treatments in hemophilia: insights for the clinician. Therapeutic Advances in Hematology, 2012, 3, 165-175.	1.1	12
155	Bone marrow mesenchymal progenitor and stem cell biology and therapy. , 2012, , 345-390.		0
156	Selective Blockade of Herpesvirus Entry Mediator-β and T Lymphocyte Attenuator Pathway Ameliorates Acute Graft-versus-Host Reaction. Journal of Immunology, 2012, 188, 4885-4896.	0.4	25
158	Multiple Single-Nucleotide Polymorphism-Based Risk Model for Clinical Outcomes After Allogeneic Stem-Cell Transplantation, Especially for Acute Graft-Versus-Host Disease. Transplantation, 2012, 94, 1250-1257.	0.5	19
159	Modern haemophilia care. Lancet, The, 2012, 379, 1447-1456.	6.3	266
160	Role of iron replacement in the management of preoperative anemia. Transfusion Alternatives in Transfusion Medicine, 2012, 12, 150-156.	0.2	4
161	Fludarabine, Busulfan, Antithymocyte Globulin, and Total Body Irradiation for Pretransplantation Conditioning in Acute Lymphoblastic Leukemia: Excellent Outcomes in All but Older Patients with Comorbidities. Biology of Blood and Marrow Transplantation, 2012, 18, 1921-1926.	2.0	25
162	Idiopathic thrombocytopenic purpura managed by intravenous anti-D. Journal of Obstetrics and Gynaecology, 2012, 32, 195-198.	0.4	0
163	Genetic Variations in the Mycophenolate Mofetil Target Enzyme Are Associated with Acute GVHD Risk After Related and Unrelated Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 273-279.	2.0	12
164	Identification of a Coordinated CD8 and CD4 T Cell Response Directed Against Mismatched HLA Class I Causing Severe Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2012, 18, 210-219.	2.0	26
165	GVHD Prevention: An Ounce Is Better Than a Pound. Biology of Blood and Marrow Transplantation, 2012, 18, S17-S26.	2.0	10
166	Myeloablative Radioimmunotherapy in Conditioning of Acute Leukemia, MDS, and Multiple Myeloma Prior to Hematological Stem Cell Transplantation. Medical Radiology, 2012, , 669-683.	0.0	0

#	ARTICLE	IF	CITATIONS
167	Acute and Chronic Skin Graft-versus-Host Disease – Pathophysiological Aspects. <i>Current Problems in Dermatology</i> , 2012, 43, 91-100.	0.8	5
168	Laboratory diagnosis of iron deficiency. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2012, 12, 95-102.	0.2	4
169	Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. <i>Leukemia</i> , 2012, 26, 582-588.	3.3	65
170	Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis. <i>International Journal of Hematology</i> , 2012, 96, 764-772.	0.7	21
172	Decreased Levels of Circulating IL17-Producing CD161+CCR6+ T Cells Are Associated with Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2012, 7, e50896.	1.1	39
173	The Role of Chemokines in Mediating Graft Versus Host Disease: Opportunities for Novel Therapeutics. <i>Frontiers in Pharmacology</i> , 2012, 3, 23.	1.6	30
174	Dendritic Cells in Hematopoietic Stem Cell Transplantation. , 0, , .		0
175	<i>F8</i> and <i>F9</i> mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. <i>Haemophilia</i> , 2012, 18, 375-382.	1.0	109
176	Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 82-93.	2.0	73
177	Continuous infusion in haemophilia: current practice in Europe. <i>Haemophilia</i> , 2012, 18, 753-759.	1.0	30
178	Elevated Fas/FasL system and endothelial cell microparticles are involved in endothelial damage in acute graft-versus-host disease: A clinical analysis. <i>Leukemia Research</i> , 2012, 36, 275-280.	0.4	21
179	Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?. <i>Bone Marrow Transplantation</i> , 2013, 48, 284-293.	1.3	22
180	Identification and characterization of an adenine to guanine transition within intron 10 of the factor <i>VIII</i> gene as a causative mutation in a patient with mild haemophilia A. <i>Haemophilia</i> , 2013, 19, 100-105.	1.0	26
181	Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1397-1404.	1.2	13
182	Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens. <i>International Journal of Hematology</i> , 2013, 97, 421-426.	0.7	3
183	Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 320-334.	1.1	53
184	The where and when of T cell regulation in transplantation. <i>Trends in Immunology</i> , 2013, 34, 107-113.	2.9	32
185	Advances in the treatment of acute graft-versus-host disease. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 966-975.	1.6	40

#	ARTICLE	IF	CITATIONS
186	Hemophilia A in the third millennium. <i>Blood Reviews</i> , 2013, 27, 179-184.	2.8	127
187	TLR4 inactivation protects from graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Cellular and Molecular Immunology</i> , 2013, 10, 165-175.	4.8	36
188	State of the iron: How to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 429-440.	0.6	71
189	Biobehavioral influences on recovery following hematopoietic stem cell transplantation. <i>Brain, Behavior, and Immunity</i> , 2013, 30, S68-S74.	2.0	60
190	Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1381-1386.	2.0	32
191	Migration and Activation of T Cells During Development of Graft-Versus-Host Disease in a Mouse Model. <i>Transplantation Proceedings</i> , 2013, 45, 713-718.	0.3	3
192	The Expression of Th17-Associated Cytokines in Human Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1421-1429.	2.0	24
193	Cellular mechanism for granulocyte-colony stimulating factor in the prevention of graft-versus-host disease in combined bone marrow and peripheral blood transplantation for hematological malignancies: The composition in collection. <i>Transfusion and Apheresis Science</i> , 2013, 48, 3-9.	0.5	8
194	Psychosocial factors and hematopoietic stem cell transplantation: Potential biobehavioral pathways. <i>Psychoneuroendocrinology</i> , 2013, 38, 2383-2393.	1.3	43
195	New ways to separate Graft-versus-Host Disease and Graft-versus-Tumour effects after allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2013, 160, 133-145.	1.2	21
196	Overview of the immune biology of allogeneic hematopoietic stem cell transplantation. , 2013, , 1-17.		2
197	Radiosynovectomy. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 465-470.	0.5	30
198	Frequency and Outcome of Graft versus Host Disease after Stem Cell Transplantation: A Six-Year Experience from a Tertiary Care Center in Pakistan. <i>ISRN Hematology</i> , 2013, 2013, 1-6.	1.6	5
199	<scp>TRBV</scp> kinetics and its association with <scp>HLA</scp> disparity and a<scp>GVHD</scp> following allogeneic hematopoietic stem cell transplantation. <i>International Journal of Laboratory Hematology</i> , 2013, 35, 119-127.	0.7	4
200	MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. <i>Blood</i> , 2013, 121, 4617-4626.	0.6	48
201	Pathobiology of graft-versus-host disease. , 0, , 297-310.		0
202	Pathophysiology of the Skin and Oral Squamous Mucosa in Allogeneic Hematopoietic Stem Cell Transplantation. , 2014, , 722-740.		0
203	Safety and efficacy of an intra-oral electrostimulator for the relief of dry mouth in patients with chronic graft versus host disease: Case Series. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2014, 19, e212-e219.	0.7	7

#	ARTICLE	IF	CITATIONS
204	Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP. <i>Journal of Leukocyte Biology</i> , 2014, 95, 677-688.	1.5	16
205	Oral Complications in Hematopoietic Stem Cell Recipients: The Role of Inflammation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-18.	1.4	48
206	Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models. <i>Bone Marrow Transplantation</i> , 2014, 49, 649-656.	1.3	18
207	Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia and inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 897-901.	1.9	11
209	Alpha/Beta T-Cell Depleted Grafts as an Immunological Booster to Treat Graft Failure after Hematopoietic Stem Cell Transplantation with HLA-Matched Related and Unrelated Donors. <i>Journal of Immunology Research</i> , 2014, 2014, 1-14.	0.9	35
210	NOD2/CARD15 Single Nucleotide Polymorphism 13 (3020insC) is Associated with Risk of Sepsis and Single Nucleotide Polymorphism 8 (2104C>T) with Herpes Viruses Reactivation in Patients after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 409-414.	2.0	17
211	Oral Graft-Versus-Host Disease. <i>Dental Clinics of North America</i> , 2014, 58, 351-368.	0.8	37
212	T-Cell Receptor Excision Circle Levels After Allogeneic Stem Cell Transplantation Are Predictive of Relapse in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Stem Cells and Development</i> , 2014, 23, 1559-1567.	1.1	8
213	Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2014, 93, 645-651.	0.8	16
214	Characterization of Oral Involvement in Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1717-1721.	2.0	33
215	Monocyte-Induced Development of Th17 Cells and the Release of S100 Proteins Are Involved in the Pathogenesis of Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2014, 193, 3355-3365.	0.4	49
216	Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells. <i>Immunity</i> , 2014, 41, 579-591.	6.6	87
217	Rationale for combination therapy in myelofibrosis. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 197-208.	0.7	20
218	Engineering Human Peripheral Blood Stem Cell Grafts that Are Depleted of Naïve T Cells and Retain Functional Pathogen-Specific Memory T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 705-716.	2.0	93
219	Depletion of Host CCR7+ Dendritic Cells Prevented Donor T Cell Tissue Tropism in Anti-CD3-Conditioned Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 920-928.	2.0	10
220	The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors. <i>Clinical Immunology</i> , 2014, 152, 48-57.	1.4	13
221	Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies. <i>World Journal of Stem Cells</i> , 2014, 6, 380.	1.3	6
222	Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. , 2014, , CD009759.		2

#	ARTICLE	IF	CITATIONS
223	Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. The Cochrane Library, 2015, , CD009759.	1.5	5
224	Identification of a novel lymphoid population in the murine epidermis. Scientific Reports, 2015, 5, 12554.	1.6	13
225	Irradiation and bone marrow reconstitution affect the functional Ly49 natural killer cell repertoire in rats. Frontiers in Cell and Developmental Biology, 2015, 3, 34.	1.8	1
226	Ocular manifestations of graft-versus-host disease: 10 years's experience. Clinical Ophthalmology, 2015, 9, 1209.	0.9	29
227	Human Albumin Eye Drops as a Therapeutic Option for the Mmanagement of Keratoconjunctivitis Sicca Secondary to Chronic Graft-Versus-Host Disease after Stem-Cell Allografting. Current Oncology, 2015, 22, 357-363.	0.9	5
228	Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood, 2015, 125, 3778-3788.	0.6	29
229	<scp>CD</scp>44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of <scp>Fc</scp>Î³RIIb genetic disruption. Transfusion, 2015, 55, 1492-1500.	0.8	10
230	Carbon nanotube-based nanocarrier loaded with ribavirin against grass carp reovirus. Antiviral Research, 2015, 118, 29-38.	1.9	35
231	The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs. Regenerative Medicine, 2015, 10, 331-343.	0.8	7
232	State-of-the-art acute and chronic GVHD treatment. International Journal of Hematology, 2015, 101, 452-466.	0.7	72
233	Identification of Suitable Reference Genes for Normalization of Real-Time Quantitative Polymerase Chain Reaction in an Intestinal Graft-Versus-Host Disease Mouse Model. Transplantation Proceedings, 2015, 47, 2017-2025.	0.3	5
234	Role of HMGB1 in regulation of STAT3 expression in CD4 + T cells from patients with aGVHD after allogeneic hematopoietic stem cell transplantation. Clinical Immunology, 2015, 161, 278-283.	1.4	22
235	The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment. Cellular and Molecular Immunology, 2015, 12, 681-691.	4.8	34
236	IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects. Leukemia, 2015, 29, 939-946.	3.3	41
237	Management of the Medically Compromised Patient. , 2016, , 540-562.		2
238	Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders. Advances in Hematology, 2016, 2016, 1-8.	0.6	10
239	Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. Viruses, 2016, 8, 85.	1.5	8
240	The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview. Frontiers in Immunology, 2016, 7, 333.	2.2	44

#	ARTICLE	IF	CITATIONS
241	PROSE Treatment for Ocular Chronic Graft-Versus-Host Disease as a Clinical Network Expands. <i>Eye and Contact Lens</i> , 2016, 42, 262-266.	0.8	22
242	Clinical Trials with Mesenchymal Stem Cells: An Update. <i>Cell Transplantation</i> , 2016, 25, 829-848.	1.2	1,107
244	LRBA is Essential for Allogeneic Responses in Bone Marrow Transplantation. <i>Scientific Reports</i> , 2016, 6, 36568.	1.6	9
245	Evaluation of interleukin 12 and CD56+ lymphocyte cells in pediatric hematopoietic stem cell transplantation for early diagnosis of acute graft versus host disease. <i>Transplant Immunology</i> , 2016, 39, 25-29.	0.6	3
246	MicroRNA-150 negatively regulates the function of CD4+ T cells through AKT3/Bim signaling pathway. <i>Cellular Immunology</i> , 2016, 306-307, 35-40.	1.4	29
248	Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression. <i>Bone Marrow Transplantation</i> , 2016, 51, 629-637.	1.3	16
249	Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 268-276.	2.0	36
250	Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 628-633.e10.	1.5	30
251	A Review of Ocular Graft-Versus-Host Disease. <i>Optometry and Vision Science</i> , 2017, 94, 545-555.	0.6	60
252	Imaging of Abdominal and Pelvic Manifestations of Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplant. <i>American Journal of Roentgenology</i> , 2017, 209, 33-45.	1.0	30
253	A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. <i>Journal of Immunotherapy</i> , 2017, 40, 132-139.	1.2	5
254	Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2017, 29, 474-483.	1.1	12
255	Remestemcel-L for the treatment of graft versus host disease. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 43-56.	1.3	33
256	Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target. <i>Frontiers in Immunology</i> , 2017, 8, 667.	2.2	49
257	Inhibition of Acute Graft-versus-Host Disease with Retention of Graft-versus-Tumor Effects by Dimethyl Fumarate. <i>Frontiers in Immunology</i> , 2017, 8, 1605.	2.2	12
258	Assessment of TREC, KREC and telomere length in long-term survivors after allogeneic HSCT: the role of GvHD and graft source and evidence for telomere homeostasis in young recipients. <i>Bone Marrow Transplantation</i> , 2018, 53, 69-77.	1.3	13
259	Immunomodulatory mechanisms of mesenchymal stem cells and their therapeutic applications. <i>Cellular Immunology</i> , 2018, 326, 68-76.	1.4	45
260	Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses. , 2018, , 1650-1668.e10.		1

#	ARTICLE	IF	CITATIONS
261	Reconstitution of the immune system after hematopoietic stem cell transplantation. <i>Hematologie</i> , 2018, 24, 60-71.	0.0	0
262	IL-17C Mitigates Murine Acute Graft-vs.-Host Disease by Promoting Intestinal Barrier Functions and Treg Differentiation. <i>Frontiers in Immunology</i> , 2018, 9, 2724.	2.2	5
263	A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. <i>Blood Advances</i> , 2018, 2, 1719-1737.	2.5	25
264	Human CD4- invariant NKT lymphocytes regulate graft versus host disease. <i>Oncolmmunology</i> , 2018, 7, e1470735.	2.1	18
265	Unexpected High Incidence of Human Herpesvirus-6 Encephalitis after Naive T Cell-Depleted Graft of Haploidentical Stem Cell Transplantation in Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2316-2323.	2.0	42
266	Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant. <i>British Journal of Haematology</i> , 2018, 182, 870-886.	1.2	15
267	The Channel-Kinase TRPM7 as Novel Regulator of Immune System Homeostasis. <i>Cells</i> , 2018, 7, 109.	1.8	43
268	Chronic graft-versus-host disease: Current management paradigm and future perspectives. <i>Oral Diseases</i> , 2019, 25, 931-948.	1.5	26
269	Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?. <i>Biomarker Research</i> , 2019, 7, 17.	2.8	13
270	Review of Graft-Versus-Host Disease. <i>Dermatologic Clinics</i> , 2019, 37, 569-582.	1.0	93
271	Graft Versus Host Disease-Associated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a Mucin Secretagogue. , 2019, 60, 4511.		17
272	Potentials of stem cell-therapy in pancreatic cancer: An update. <i>Pancreatology</i> , 2019, 19, 1034-1042.	0.5	15
273	Overview of the Immune Biology of Allogeneic HSCT. , 2019, , 1-14.		1
274	Statins in ophthalmology. <i>Survey of Ophthalmology</i> , 2019, 64, 401-432.	1.7	29
275	Oral Manifestations of Systemic Diseases and Their Treatments. , 2019, , 1523-1639.		1
276	Donor-derived CD4+/CCR7+ T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2019, 54, 1686-1693.	1.3	3
277	A Pilot Study of Human Milk to Reduce Intestinal Inflammation After Bone Marrow Transplant. <i>Breastfeeding Medicine</i> , 2019, 14, 193-202.	0.8	12
278	BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. <i>Frontiers in Immunology</i> , 2018, 9, 3104.	2.2	20



#	ARTICLE	IF	CITATIONS
279	Vitamin D-modulated dendritic cells delay lethal graft-versus-host disease through induction of regulatory T cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 188, 103-110.	1.2	26
280	Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 669-677.	1.1	17
281	Long-term treatment with the P2X7 receptor antagonist Brilliant Blue G reduces liver inflammation in a humanized mouse model of graft-versus-host disease. <i>Cellular Immunology</i> , 2019, 336, 12-19.	1.4	19
282	Checkpoint inhibitors in AML: are we there yet?. <i>British Journal of Haematology</i> , 2020, 188, 159-167.	1.2	31
283	Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 408-420.	2.0	57
284	Profile of Hepatobiliary Dysfunction in Hematopoietic Stem Cell Transplant Recipients – An Indian Perspective. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 14-20.	0.4	3
285	Mesenchymal Stromal Cells Rapidly Suppress TCR Signaling-Mediated Cytokine Transcription in Activated T Cells Through the ICAM-1/CD43 Interaction. <i>Frontiers in Immunology</i> , 2021, 12, 609544.	2.2	8
286	Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 651751.	2.2	8
287	Sleep Disruption, Fatigue, and Depression as Predictors of 6-Year Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1405-1414.	3.0	13
288	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. <i>Haematologica</i> , 2022, 107, 1054-1063.	1.7	20
289	A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin. <i>Cytotherapy</i> , 2021, 23, 1007-1016.	0.3	4
290	Ultra-High Dose Vitamin D in Pediatric Hematopoietic Stem Cell Transplantation: A Nonrandomized Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1001.e1-1001.e9.	0.6	6
291	Involvement of ocular surface in graft-versus-host disease: An update from immunopathogenesis to treatment. <i>Journal of Cellular Physiology</i> , 2021, 236, 6190-6199.	2.0	6
292	Biology and Management of Acute Graft-Versus-Host Disease. <i>Cancer Treatment and Research</i> , 2009, 144, 257-275.	0.2	5
293	Pathophysiology of Acute Graft-versus-Host Disease. , 2008, , 563-588.		1
294	Cellular Therapy for Hematology Malignancies: Allogeneic Hematopoietic Stem Transplantation, Graft-Versus-Host Disease, and Graft Versus Leukemia Effects. , 2012, , 303-366.		1
295	Mechanism of HPSE Gene SNPs Function: From Normal Processes to Inflammation, Cancerogenesis and Tumor Progression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1221, 231-249.	0.8	6
296	Oral Manifestations of Systemic Diseases and their Treatments. , 2018, , 1-117.		4

#	ARTICLE	IF	CITATIONS
297	Promises and limitations of targeting adhesion molecules for therapy. , 2007, , 289-303.		2
298	Transplantation Pathology of the Liver. , 2009, , 1169-1229.		8
299	Ceramide synthesis regulates T cell activity and GVHD development. JCI Insight, 2017, 2, .	2.3	49
300	Correlation of IL-6 and IL-10 production following bone marrow transplantation with donor cytokine gene polymorphisms. Revista Brasileira De Hematologia E Hemoterapia, 2008, 30, .	0.7	1
301	Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy, 2009, 1, 599-621.	1.0	62
302	Induction of Mixed Chimerism for Reversal of Autoimmunity in Type 1 Diabetes. Journal of Clinical & Cellular Immunology, 2011, , .	1.5	5
303	Graft Versus Host Disease. , 2021, , 1-23.		0
304	Sarcoidosis Following Hematopoietic Stem Cell Transplantation: Clinical Characteristics and HLA Associations. Frontiers in Immunology, 2021, 12, 746996.	2.2	3
305	Therapeutic Effect of CXCR3-Expressing Regulatory T Cells on Liver and Intestinal Damages in a Murine Acute GVHD Model.. Blood, 2007, 110, 2161-2161.	0.6	0
307	Distribution of CD4+CD25+ T cells and graft-versus-host disease in human hematopoietic stem cell transplantation. Korean Journal of Pediatrics, 2008, 51, 1336.	1.9	0
309	Alloreactive T Cells for the Treatment of Leukemia. , 2010, , 397-411.		0
310	The Role of the Thymus in Hematopoietic Stem Cell Transplantation. , 2010, , 303-350.		0
311	Allogeneic Cell Therapy. , 2011, , 140-142.		0
314	Therapeutic Application of Amniotic Fluid Stem Cells for Graft-Versus-Host Disease. , 2014, , 43-52.		0
315	Hematopoietic Stem Cell Transplantation and Lymphodepletion for the Treatment of Cancer. , 2015, , 189-201.		0
317	Allogeneic Cell Therapy. , 2015, , 187-190.		0
319	Graft Versus Host Disease (GVHD). , 2016, , 429-449.		0
320	Cutaneous Graft-Versus-Host Disease. , 2017, , 665-683.		0

#	ARTICLE	IF	CITATIONS
321	ICU Complications of Hematopoietic Stem Cell Transplantation Including Graft Versus Host Disease. , 2017, , 631-640.		0
322	Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia. <i>Experimental and Clinical Transplantation</i> , 2018, 16, 736-744.	0.2	0
323	CCR4 as a Therapeutic Target for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5542.	1.7	47
327	Principles of bone marrow transplantation (BMT): providing optimal veterinary and husbandry care to irradiated mice in BMT studies. <i>Journal of the American Association for Laboratory Animal Science</i> , 2009, 48, 11-22.	0.6	113
329	Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen. <i>International Journal of Clinical and Experimental Pathology</i> , 2011, 4, 596-605.	0.5	8
330	Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations. <i>Journal of Ophthalmic and Vision Research</i> , 2013, 8, 351-8.	0.7	45
331	Bortezomib inhibits bone marrow-derived dendritic cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 4857-62.	0.5	6
332	Proinflammatory cytokines as potential risk factors of acute graft-versus-host disease and infectious complications after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Blood Research</i> , 2021, 11, 149-156.	0.6	0
333	Oral chronic GVHD after allogeneic stem cell transplantation without total body irradiation performed at a young age. <i>Supportive Care in Cancer</i> , 2022, 30, 4121.	1.0	1
334	Diagnosis and staging of ophthalmic manifestations of the graft-versus-host reaction after allogeneic hematopoietic stem cell transplantation. <i>Ophthalmology Journal</i> , 2021, 14, 91-102.	0.1	1
337	Graft Versus Host Disease. , 2022, , 7557-7579.		0
338	Multimiomics Analysis Identifies SOCS1 as Restraining T Cell Activation and Preventing Graftâ€Versusâ€Host Disease. <i>Advanced Science</i> , 2022, 9, e2200978.	5.6	7
339	Noncoding RNAs in diagnosis and prognosis of graftâ€versusâ€host disease (GVHD). <i>Journal of Cellular Physiology</i> , 2022, 237, 3480-3495.	2.0	4
340	Insights into mechanisms of graft-versus-host disease through humanised mouse models. <i>Bioscience Reports</i> , 2022, 42, .	1.1	7
341	Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation. <i>World Journal of Biological Chemistry</i> , 0, 13, 72-82.	1.7	0
342	Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents. <i>The Cochrane Library</i> , 2022, .	1.5	0
343	Immunopathological insights into villitis of unknown etiology on the basis of transplant immunology. <i>Placenta</i> , 2023, 131, 49-57.	0.7	1
344	Advances in Imaging of Inflammation, Fibrosis, and Cancer in the Gastrointestinal Tract. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16109.	1.8	7

#	ARTICLE	IF	CITATIONS
345	Donor Genetic Predisposition to High Interleukin-10 Production Appears Protective against Acute Graft-Versus-Host Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15888.	1.8	1
347	Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation. <i>Cell Reports</i> , 2023, 42, 112250.	2.9	2
348	Assessment of the therapeutic role of mesenchymal stromal cells in a mouse model of graft-versus-host disease using cryo-imaging. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
349	A cofunctional grouping-based approach for non-redundant feature gene selection in unannotated single-cell RNA-seq analysis. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	1
350	Whole-genome sequencing and genomic analysis of Norduz goat ( <i>Capra hircus</i> ). <i>Mammalian Genome</i> , 0, , .	1.0	0
355	Acute Graft-Versus-Host Disease. , 2023, , 573-608.		0